Jefferies Starts ProNAi Therapeutics (DNAI) at Buy

Jefferies initiates coverage on ProNAi Therapeutics (NASDAQ: DNAI) with a Buy rating and a price target of $37.00.

Analyst Brian Abrahams commented, "ProNAi is developing PNT2258, a Bcl2-directed oligonucleotide, in ph.II for hematological cancers. We believe DNAI is undervalued based on ‘2258’s promise in DLBCL and Richter’s, stemming from what we and our KOL consultants view as impressive single-agent activity in a handful of R/R DLBCL patients, with long-term upside potential from additional combos/indications and the underlying DNAi platform technology."

For an analyst ratings summary and ratings history on ProNAi Therapeutics click here. For more ratings news on ProNAi Therapeutics click here.

Shares of ProNAi Therapeutics closed at $28.56 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Krystal Biotech (KRYS) PT Raised to $396 at BofA Securities
• Tigress Financial Partners Starts Liftoff Mobile (LFTO) at Buy